Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: An in vivo toxicity assay

Molecular Vision

Volumn 15, Issue , 2009, Pages 1690-1699

  Liang, Hong ^a,b,c,d   Baudouin, Christophe ^b,c,d,e   Faure, Marie Odile ^f   Lambert, Grégory ^f   Brignole Baudouin, Françoise ^a,b,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT DE LA VISION   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f Novagali Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; BIMATOPROST; LATANOPROST; PHOSPHATE BUFFERED SALINE; TRAVOPROST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMICROSCOPY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; CORNEA LIMBUS; DRUG FORMULATION; DRUG TOLERANCE; EMULSION; EXPERIMENTAL RABBIT; EYE TOXICITY; FLOW CYTOMETRY; IMPRESSION CYTOLOGY; IN VIVO STUDY; LYMPHOID TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING;

ANIMALS; ANTIGENS, CD45; CATIONS; CONJUNCTIVA; EMULSIONS; EYE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPHOID TISSUE; MALE; MICROSCOPY, CONFOCAL; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS; PROSTAGLANDINS F, SYNTHETIC; RABBITS; TOXICITY TESTS;

EID: 69449097521     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ 2004; 82:887-8.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90:262-7.
3. Ishida N, Odani-Kawabata N, Shimazaki A, Hara H. Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev 2006; 24:1-10.
4. Herman JR, Bass P. Enteric neuronal ablation: structure-activity relationship in a series of alkyldimethylbenzylammonium chlorides. Fundam Appl Toxicol 1989; 13:576-84.
5. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 1994; 101:454-60.
6. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007; 48:4123-8.
7. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005; 46:4594-9.
8. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005; 46:2444-50.
9. Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, Baudouin C. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004; 45:1360-8.
10. Okada Y. Effects of topical antiglaucoma medications on corneal epithelium as evaluated by gene expression patterns. Cornea 2007; 26:S46-54.
11. Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998; 82:39-42.
12. Brasnu E, Brignole-Baudouin F, Riancho L, Guenoun JM, Warnet JM, Baudouin C. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res 2008; 33:303-12.
13. Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short-and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 2008; 92:1275-82.
14. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341-9.
15. Tamilvanan S, Benita S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm 2004; 58:357-68.
16. Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular drug delivery. J Drug Target 2004; 12:623-33.
17. Klang S, Abdulrazik M, Benita S. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol 2000; 5:521-32.
18. Rabinovich-Guilatt L, Abdulrazik M, Benita S, Lambert G. Cationic emulsions as innovative treatments for dry eye. Proceedings of the 6th International Symposium on Ocular Pharmacology and Therapeutics 2006
19. Liang H, Brignole-Baudouin F, Rabinovich-Guilatt L, Mao Z, Riancho L, Faure MO, Warnet JM, Lambert G, Baudouin C. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis 2008; 14:204-16.
20. Lambert G. Preclinical development of a new cyclosporine A eye drop emulsion. Proceedings of the 9th International Congress of International Ocular Inflammation Society 2007:17-20.
21. Lambert G, Rabinovich-Guilatt L. Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjuctivitis sicca (VKC). ARVO Annual Meeting; 2007 May 6-10; Fort Lauderdale (FL).
22. Ichijima H, Petroll WM, Jester JV, Cavanagh HD. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 1992; 11:221-5.
23. Liang H, Baudouin C, Dupas B, Brignole F. Live conjunctiva-associated lymphoid associated tissue (CALT) analysis in rabbit using in vivo confocal microscopy (IVCM) under inflammatory stimuli. Invest Ophthalmol Vis Sci 2009; In correction.
24. Pauly A, Labbe A, Baudouin C, Liang H, Warnet JM, Brignole-Baudouin F. In vivo confocal microscopic grading system for standardized corneal evaluation: application to toxic-induced damage in rat. Curr Eye Res 2008; 33:826-38.
25. Haller-Schober EM, Schwantzer G, Berghold A, Fischl M, Theisl A, Horwath-Winter J. Evaluating an impression cytology grading system (IC score) in patients with dry eye syndrome. Eye 2006; 20:927-33.
26. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther 2006; 23:511-9.
27. McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride. J Ocul Pharmacol Ther 2007; 23:445-51.
28. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006; 23:663-71.
29. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008; 27:339-43.
30. Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res 2009; 41:118-22.
31. Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf) 2008; 242:14-9.
32. Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf) 2008; 242:7-13.
33. Krzystyniak K, Tryphonas H, Fournier M. Approaches to the evaluation of chemical-induced immunotoxicity. Environ Health Perspect 1995; 103:17-22.
34. Wang M, Kitahara Y, Yoshida A, Hori J. Latanoprost does not affect immune privilege of corneal allografts. Exp Eye Res 2008; 86:394-402.
35. Steven P, Gebert A. Conjunctiva-Associated Lymphoid Tissue - Current Knowledge, Animal Models and Experimental Prospects. Ophthalmic Res 2009; 42:2-8.
36. Knop E, Knop N. The role of eye-associated lymphoid tissue in corneal immune protection. J Anat 2005; 206:271-85.